Vabysmo (faricimab-svoa) / Roche, Xoma - LARVOL DELTA

Economic Evaluation of Bispecific Antibodies in Europe: A Systematic Review (ISPOR-EU 2025) - "In France, emicizumab and blinatumomab were found to be dominant and cost-‍effective treatments for patients with haemophilia A with inhibitors and patients with high-‍risk first-relapse B-cell precursor acute lymphoblastic leukaemia, respectively, compared with relevant alternatives. Elranatamab was cost-effective compared with physician's choice of treatment (incremental cost-effectiveness ratio: €24,754/quality-‍adjusted life year [QALY]) for relapsed/refractory multiple myeloma in Spain, outperforming teclistamab, providing 0.60 additional QALYs and saving €101,026. In the UK, faricimab dominated over aflibercept, with total cost savings of £15,108,609 and 60.06 QALYs gained for patients with wet age-related macular degeneration or diabetic macular oedema. Our review showed that most bispecific antibodies were either highly effective or cost-efficient. Implementing these treatments can lead to improved health outcomes and significant economic advantages in..."

HEOR • Review • Acute Lymphocytic Leukemia • Age-related Macular Degeneration • Diabetic Macular Edema • Hematological Disorders • Hematological Malignancies • Hemophilia • Hemophilia A • Leukemia • Macular Degeneration • Macular Edema • Multiple Myeloma • Ophthalmology • Rare Diseases • Retinal Disorders • Wet Age-related Macular Degeneration

Factors associated with patient-initiated discontinuation of anti-vascular endothelial growth factor therapy for diabetic macular edema: a real-world study in Japan. (PubMed, Jpn J Ophthalmol) - "The findings of this study underscore the importance of individualized patient management strategies to enhance long-term adherence to anti-VEGF therapy among patients with DME."

Journal • Real-world evidence • Diabetic Macular Edema • Ophthalmology

Faricimab treat-and-extend approach for neovascular age-related macular degeneration: insights from real-world clinical practice. (PubMed, Int J Retina Vitreous) - "The switch to faricimab in a T&E regimen significantly increased treatment intervals maintaining BCVA in patients with nAMD under other anti-VEGF treatments. No serious adverse events were reported. Longer follow-up is needed to confirm these results."

Journal • Real-world evidence • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Quantitative analysis of vitreous changes in intraocular inflammation following faricimab treatment in a real world setting. (PubMed, Int J Retina Vitreous) - No abstract available

Journal • Real-world evidence • Inflammation • Ocular Inflammation

Network Meta-Analysis of Bevacizumab Gamma Versus Competing Interventions for Treating Neovascular Age-Related Macular Degeneration in the United Kingdom. (PubMed, J Mark Access Health Policy) - "The included anti-VEGF treatments were ranibizumab, aflibercept, faricimab, and bevacizumab gamma. At 12 months, all anti-VEGF treatments were similarly efficacious to ranibizumab 0.5 mg every four weeks (Q4W) in terms of CFB in BCVA, the proportion of patients gaining 15 or more letters, and the proportion of patients losing less than 15 letters (except for ranibizumab 0.5 mg every 12 weeks [Q12W] and ranibizumab 0.5 mg pro re nata [PRN]). Bevacizumab gamma provided similar improvements in visual acuity to other anti-VEGF treatments."

Journal • Retrospective data • Review • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Full-Thickness Macular Hole After Faricimab Treatment for Branch Retinal Vein Occlusion-Associated Macular Edema with Vitreomacular Traction: A Case Report. (PubMed, Am J Case Rep) - "This appears to be the first reported case following faricimab treatment for BRVO-associated CME, underscoring the need for careful pretreatment evaluation of the vitreoretinal interface and awareness of potential tractional complications. Individualized treatment strategies may help reduce such risks and improve outcomes."

Journal • Cataract • Macular Edema • Ophthalmology • Retinal Disorders • Retinal Vein Occlusion

Novel Needle for Intravitreal Injections Does Not Affect Biological Activity of Anti-VEGF Drugs. (PubMed, Clin Ophthalmol) - "Anti-VEGF drugs, such as ranibizumab, faricimab, and aflibercept, were passed twice through one of the two needle types to imitate IVI. The passage of the proteins through NDN or SHN did neither affect efficient binding to their target, nor their capacity to prevent VEGF-A165-induced barrier dysfunction. Overall, regarding the stability of therapeutic proteins, the NDN was not inferior to the SHN, and can now be considered for evaluation in clinical studies."

Journal • Inflammation • Ocular Infections • Ocular Inflammation • Ophthalmology

Neovascular age-related macular degeneration complicated by large submacular hemorrhage managed with faricimab monotherapy. (PubMed, Int J Retina Vitreous) - No abstract available

Journal • Monotherapy • Age-related Macular Degeneration • Hematological Disorders • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

High-Dose 8 mg Aflibercept for Neovascular Age-Related Macular Degeneration: Who Is Being Treated with This New Agent? (PubMed, Life (Basel)) - "The last treatment before switching was 2 mg aflibercept in 76%, faricimab in 18%, ranibizumab in 3% and bevacizumab in 3% of cases...The main reasons for switching were recalcitrant nAMD with persistent fluid despite q4w dosing (50%) or the wish for treatment extension beyond 6 weeks (32%). In the future, these data will aid in the design of prospective real-world studies comparing the efficacy of high-dose 8 mg aflibercept with older generation treatment options, especially 2 mg aflibercept."

Journal • Age-related Macular Degeneration • Hematological Disorders • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Early anatomical outcomes of faricimab vs. aflibercept 2 mg in treatment-naïve neovascular AMD and PCV: A head-to-head comparative study in Taiwan. (PubMed, J Chin Med Assoc) - "Faricimab and aflibercept demonstrated comparable effects on BCVA, CMT, and SFCT. However, faricimab was associated with better early control of PED, SHRM, and HRF. Further prospective trials are needed to validate our findings."

Head-to-Head • Journal • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Comparative efficacy and safety of faricimab, aflibercept, conbercept, and ranibizumab for neovascular age-related macular degeneration: a systematic review and network meta-analysis. (PubMed, Eur J Pharmacol) - "Aflibercept and conbercept may be preferred when anatomical outcomes are prioritized, whereas faricimab's extended dosing interval could benefit treatment-adherent populations. The superior safety profile of aflibercept 2 mg warrants consideration in risk averse patients. These differential effects support personalized therapeutic decision-making."

Journal • Retrospective data • Review • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

M-VIVA: Identification of Molecular Signals in Vitreous Humor Associated With Suboptimal Response to Vascular Endothelial Growth Factor (VEGF) Inhibition in Neovascular Age-related Macular Degeneration (nAMD) Within a Clinical Trial Setting (clinicaltrials.gov) - P=N/A | N=117 | Recruiting | Sponsor: Singapore National Eye Centre

New trial • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration • CXCL8

Drug-induced immune-mediated uveitis: a real-world pharmacovigilance analysis using FAERS and JADER databases. (PubMed, BMJ Open Ophthalmol) - "Our study highlights the diverse range of drugs implicated in the occurrence or progression of IMU. These findings emphasise the need for early risk assessment, careful monitoring and positive intervention in managing treatments involving high-risk drugs. Future research should focus on elucidating underlying mechanisms and risk factors to develop safer therapeutic strategies."

Adverse events • Journal • Real-world evidence • Retrospective data • Inflammation • Musculoskeletal Diseases • Ocular Inflammation • Oncology • Ophthalmology • Uveitis

Computational modeling of anti-VEGFA drug interactions with VEGF-A: Insights into therapeutic strategies for neovascular AMD. (PubMed, Comput Biol Chem) - "In this study, we performed the first integrated in silico evaluation of six clinically relevant anti-VEGF drugs: abicipar, aflibercept, bevacizumab, brolucizumab, faricimab, and ranibizumab. This systematic analysis highlights the coexistence of evolutionary conservation and rational molecular engineering as complementary strategies shaping anti-VEGF drug performance. Overall, our findings demonstrate that computational modeling offers a cost-effective and predictive tool to guide the optimization of current therapies and the rational design of next-generation anti-VEGF agents for nAMD and other retinal vascular disorders."

Journal • Age-related Macular Degeneration • Cardiovascular • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Efficacy of faricimab for recalcitrant multifactorial cystoid macular edema. (PubMed, Am J Ophthalmol Case Rep) - "This manuscript describes a case of recalcitrant postoperative cystoid macular edema (CME), confounded by a history of branch retinal vein occlusion (BRVO), in which faricimab resulted in resolution of CME after incomplete response to topical anti-inflammation drops, intravitreal aflibercept and bevacizumab, a corticosteroid intravitreal implant, grid laser therapy, and suprachoroidal triamcinolone acetonide (SCS-TA)...CME persisted for eight years despite treatment with topical anti-inflammatories, anti-VEGF injections, a dexamethasone intravitreal implant, grid laser therapy, and a SCS-TA injection...This case demonstrates the effectiveness of faricimab in treatment of CME resistant to other therapies and the importance of continued attempts at using new agents for chronic, recurrent CME. The unique benefits of new agents like faricimab, with both VEGF and Ang-2 inhibition, may be particularly helpful in mixed or inflammatory CME when other proven therapies have failed."

Journal • Age-related Macular Degeneration • Cardiovascular • Diabetic Macular Edema • Glaucoma • Inflammation • Macular Degeneration • Macular Edema • Ophthalmology • Retinal Disorders • Retinal Vein Occlusion • Wet Age-related Macular Degeneration

Intravitreal faricimab in patients with aflibercept-refractory neovascular age-related macular degeneration: short and long-term outcomes and assessment of volume dynamics using an artificial intelligence-based tool. (PubMed, Int J Retina Vitreous) - "Faricimab may offer a valuable alternative for patients with refractory nAMD. The use of four loading injections administered monthly, followed by a treat-and-extend regimen can result in maintenance of visual acuity and improve anatomical parameters and retinal fluid activity, allowing for longer treatment intervals."

Journal • Age-related Macular Degeneration • Diabetic Retinopathy • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Real World Evidence in China: Faricimab Use in Diabetic Macular Edema, Retinal Vein Occlusion, and Neovascular Age-Related Macular Degeneration (The Farseeing Study) (clinicaltrials.gov) - P=N/A | N=1000 | Active, not recruiting | Sponsor: Hoffmann-La Roche | Trial primary completion date: Nov 2027 ➔ Nov 2026 | Recruiting ➔ Active, not recruiting

Enrollment closed • HEOR • Real-world evidence • Trial primary completion date • Age-related Macular Degeneration • Diabetic Macular Edema • Macular Degeneration • Ophthalmology • Retinal Disorders • Retinal Vein Occlusion • Wet Age-related Macular Degeneration

Environmental and Financial Cost Savings With Low-Consumption Intravitreal Injection Techniques. (PubMed, J Vitreoretin Dis) - " The authors conducted a life cycle assessment of all supplies consumed during intravitreal injections of bevacizumab, aflibercept 2 mg, aflibercept 8 mg, and faricimab at a single academic institution. Limiting supply consumption for all injections to protocol 1 may save more than 800 tons in waste, more than $500 million in cost, and 120 000 metric tons of carbon dioxide equivalents annually. Decreasing supply consumption during intravitreal injections with procedural variations, including the removal of speculums, calipers, or sterile gloves, may yield significant reductions in financial costs and environmental impact."

HEOR • Journal

First cancer medicine available in private hospitals (NZ Doctor) - "Pharmac has made decisions to: Fund new, more convenient options for medicines already funded as IV (into a vein) infusions: Subcutaneous ocrelizumab (Ocrevus SC) for multiple sclerosis...Faricimab (Vabysmo) for diabetic macular oedema and wet age-related macular degeneration (eye conditions)....Bevacizumab (Avastin) for people with eye conditions."

Reimbursement • Diabetic Macular Edema • Multiple Sclerosis • Retinal Disorders • Wet Age-related Macular Degeneration

The Cost of Pressure: Quantifying the Consequences of Clinical Strain in Ophthalmology (ISPOR-EU 2025) - "Innovative therapies that are more durable in clinical practice have the potential to significantly improve key clinical service indicators, reduce service pressures and mitigate litigation-related costs."

Clinical • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Societal Value of Intravitreal Injections for Retinal Vascular Diseases in the National Reimbursement Drug List in China (ISPOR-EU 2025) - "However, calculation of these drugs' societal value remains unexplored. The societal value of 4 therapies for the diseases from 2024 to 2033 was estimated, which are currently included in the National Reimbursement Drug List (NRDL), namely faricimab, aflibercept, ranibizumab, and conbercept. Intravitreal injections demonstrate great societal value and significant improvement in quality of life for patients with retinal vascular diseases. Our findings further provide a new perspective for the NRDL to assess innovative drugs' value, underscoring the importance of multiple dimensions in the assessment of the value of innovative medication."

Reimbursement • US reimbursement • Age-related Macular Degeneration • Cardiovascular • Diabetic Macular Edema • Macular Degeneration • Ophthalmology • Retinal Disorders • Retinal Vein Occlusion • Wet Age-related Macular Degeneration

Real-World Cost-Utility of Faricimab vs. Current and Future Anti-VEGF Therapies in Patients With Neovascular Age-Related Macular Degeneration in Italy (ISPOR-EU 2025) - P | "Faricimab was cost-effective compared to current and future anti-VEGF biosimilars for nAMD treatment in the Italian real-world setting across both scenarios. Its value, driven by improved durability and persistence, is further strengthened when indirect costs are considered."

Clinical • HEOR • Real-world • Real-world evidence • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Faricimab vs. Aflibercept 8 mg in Patients With Neovascular Age-Related Macular Degeneration: A Cost-Utility Analysis in Italy (ISPOR-EU 2025) - "This analysis indicates that faricimab T&E might be a cost-effective strategy in the treatment of nAMD in Italy when compared to aflibercept 8mg using treatment criteria aligned with clinical practice, from both NHS and societal perspectives. Those results also highlight the importance of treatment criteria and their harmonization conducting economic comparisons between anti-VEGF products."

Clinical • HEOR • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Economic Impact of Faricimab in Neovascular Age-Related Macular Degeneration Management in France (ISPOR-EU 2025) - "The integration of Faricimab into the therapeutic strategy for nAMD in France leads to substantial cost savings for the healthcare system. These savings are primarily driven by the reduced number of intravitreal injections required with Faricimab compared to other anti-VEGF therapies. Even moderately, the savings associated with the introduction of Faricimab are even greater when considered from a societal perspective."

HEOR • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

The Value of Persistence in Neovascular Age-Related Macular Degeneration (ISPOR-EU 2025) - "Effective and appropriately administered therapies, such as faricimab in the TENAYA and LUCERNE studies, yield substantial and sustainable vision improvements... Persistence with effective treatment is paramount for patients with nAMD. Discontinuation of therapy carries a high risk of disease recurrence and vision deterioration, underscoring that in nAMD, persistence equals vision and preservation of quality of life."

Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration